Please assess the completion status of the following clinical trial:

Trial Title: A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the HGS1006-C1056 protocol in the United States through Week 72 visit.~* Be able to receive 1st dose of belimumab for HGS 1006-c1066 four weeks after last dose in HGS1006-c1056.~Exclusion Criteria:~* Have developed any other medical disease or condition that has made the subject unsuitable for this study in the opinion of their physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belimumab 1 mg/kg (Type: EXPERIMENTAL): Belimumab 1 mg/kg IV every 28 days
- Belimumab 10 mg/kg (Type: EXPERIMENTAL): Belimumab 10 mg/kg IV every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).